Senores Pharmaceuticals Chart
Senores Pharmaceuticals Share Key Metrics
Volume
2.43 L
Market Cap
3629.02 CR
LTQ@LTP
14@788.00
ATP
789.22
Var Margin
18.88 %
Circuit Range
624.65-936.95
Delivery %
40.65 %
Value
19.21 CR
ASM/GSM
No
Market Lot
1
Summary
Senores Pharmaceuticals Fundamentals
View MoreP/E Ratio
35.72
P/B Ratio
4.28
Div. Yield
0
Sector P/E
58.52
Sector P/B
3.11
Sec. Div. Yield
0.6
Senores Pharmaceuticals Resistance and Support
Pivot 777
Resistance
First Resistance
798.8
Second Resistance
816.8
Third Resistance
838.6
Support
First Support
759
Second Support
737.2
Third Support
719.2
Senores Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-01-20 | Quarterly Results & Others |
| 2026-01-07 | Others |
| 2025-11-06 | Quarterly Results |
| 2025-07-23 | Quarterly Results & Others |
| 2025-05-15 | Audited Results |
| 2025-01-23 | Quarterly Results & Others |
Senores Pharmaceuticals News
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting Held On March 28, 2026
Senores Pharmaceuticals Board approved the allotment of 11.70 lakh warrants convertible into equity shares on a preferential basis. These warrants are priced at ₹812 each, totaling ₹95.00 crore, with ₹23.75 crore received upfront from promoters and promoter group entities.
Mar 28 2026 12:03:00
Senores Pharmaceuticals Limited
Senores Pharmaceuticals appointed Jatin Gajjar as Chief Technology Officer, effective March 17, 2026. Gajjar brings over three decades of leadership in pharmaceutical technology, manufacturing, and product development. Simultaneously, Manohar Lalge resigned from the company on the same date.
Mar 17 2026 16:03:00
About Senores Pharmaceuticals
NSE : 28888
BSE : 544319
ISIN : INE0RB801010
Our Company was originally incorporated as “Senores Pharmaceuticals Private Limited” a private limited company under the Companies Act 2013 through certificate of incorporation dated December 26 2017 issued by the Registrar of Companies Central Registration Centre.The name of the Company was thereafter changed to “Senores Pharmaceuticals Limited” upon conversion to a public limited company pursuant to a Board resolution dated August 1 2023 a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24 2023 and the approval of the central government dated September 4 2023 and consequently a fresh certificate of incorporation dated September 4 2023 was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.2022- Started the domestic business with a launch of the critical care injectables2023- Acquired majority stake in Havix. making it a Subsidiary of our Company- Consolidated our presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited making a Subsidiary of our Company.2024- Launched first CMO product in the US with Jubilant Cadista
Senores Pharmaceuticals Management
| Name | Position |
|---|---|
| Mr. Sanjay Shaileshbhai Majmudar | Chairman |
| Mr. Swapnil Jatinbhai Shah | Managing Director |
Senores Pharmaceuticals Similar Stocks
Nephrocare Health Services Ltd.
515.50
-15.70 (2.96%)
Supriya Lifescience Ltd.
587.55
-5.05 (0.85%)
Innova Captab Ltd.
671.35
-40.20 (5.65%)
SMS Pharmaceuticals Ltd.
386.15
-18.40 (4.55%)
Indraprastha Medical Corporation Ltd.
385.25
-19.90 (4.91%)
Artemis Medicare Services Ltd.
215.92
-9.77 (4.33%)
Suven Life Sciences Ltd.
130.19
-3.68 (2.75%)
Gujarat Themis Biosyn Ltd.
251.80
-16.35 (6.10%)
RPG Life Sciences Ltd.
1856.00
-65.50 (3.41%)
Aarti Drugs Ltd.
330.70
-10.40 (3.05%)
Senores Pharmaceuticals FAQs
